Mail

Cannabis Stocks

Cannabis Stocks

81.91k followers • 22 symbols Watchlist by Yahoo Finance

Follow this list to discover and track the stock of publicly traded companies with exposure to cannabis

22 symbols

Get the Yahoo Finance app

Free real-time data
News and price alerts
Add and edit holdings
Track performance
Create multiple watchlists

Zacks1 hour ago
Altria (MO) Earnings Expected to Grow: Should You Buy?
Altria (MO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks2 hours ago
Biogen (BIIB) Up on Q2 Earnings & Sales Beat, Raised View
Biogen (BIIB) reports encouraging second-quarter results. Shares rise in pre-market trading.
Motley Fool2 hours ago
An Old Bull on New Age Beverages Is a New Bear
Northland downgrades the functional beverage specialist, slashing its price target in the process.
Zacks3 hours ago
Things You Need to Know Before AB InBev's (BUD) Q2 Earnings
AB InBev (BUD) is poised for growth in second-quarter 2019, owing to strong sales trend and persistent strength in global brands. However, weakness in some markets and soft beer volume may affect results.
Zacks3 hours ago
Smokeless Unit & Pricing to Boost Altria's (MO) Q2 Earnings
Altria's (MO) Q2 performance is likely to gain from RRPs, high pricing and saving initiatives.
Zacks4 hours ago
Will Humira & Other Drugs Drive AbbVie's (ABBV) Q2 Earnings?
Steady rise in demand for Humira in the United States and strong growth of Imbruvica are expected to drive AbbVie's (ABBV) second-quarter sales.
Motley Fool4 hours ago
Here's How Much Legal Marijuana Canada Has Sold Since Legalizing Adult-Use Cannabis
It's probably a smaller amount than you would have expected.
Market Realist4 hours ago
Medical Cannabis for Heart and Blood Pressure Patients
Medical cannabis is gaining widespread acceptance due to increased awareness. Several countries are looking into cannabis as an alternative for existing medicine.
Motley Fool5 hours ago
3 Possible Buyers of Troubled Pot Stock CannTrust Holdings
With rumors of a white knight swirling, the following three cannabis stocks may make perfect suitors.
Financial Times12 hours ago
Can a European listing reduce the massive discount at Naspers?
FT premium subscribers can click here to receive Due Diligence every day by email. One thing to start: London’s top corporate lawyers took home record pay last year. Get the details here . Now on to the ...
Motley Fool17 hours ago
CannTrust Fires Off Response to Compliance Controversy
The company says it provides answers to regulator Health Canada's noncompliance report.
Zacks18 hours ago
Altria (MO) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Altria (MO) closed at $49.70, marking a -1.64% move from the previous day.
Zacks18 hours ago
AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, AbbVie (ABBV) closed at $68, marking a -0.79% move from the previous day.
Zacks18 hours ago
Canopy Growth Corporation (CGC) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Canopy Growth Corporation (CGC) closed at $34.86, marking a -1.76% move from the previous day.
Market Realist19 hours ago
IIPR Continues to Slump Ahead of Its Earnings
Innovative Industrial Properties (IIPR) continued to slump on July 22. The stock lost almost 6.8% of its value on the day.
Zacksyesterday
Q2 Earnings Surprise in the Cards, Healthcare ETFs to Buy
With earnings surprise in cards, the healthcare sector is expected to witness earnings growth of 1.7% in the second quarter, suggesting continued outperformance for healthcare ETFs.
Zacksyesterday
Can Allergan (AGN) Keep the Earnings Streak Alive in Q2?
While Allergan's (AGN) Q2 sales are likely to be driven by new as well as established products like Botox, generic competition for some key products is expected to hurt sales.
Zacksyesterday
Is a Beat in Store for AbbVie (ABBV) This Earnings Season?
Rising demand for Humira in the United States and strong growth of Imbruvica are expected to drive AbbVie's (ABBV) second-quarter sales.
Zacksyesterday
AB InBev (BUD) Looks Good: Stock Adds 5.5% in Session
AB InBev (BUD) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Motley Foolyesterday
Everything You Need to Know About Marijuana Legalization 2.0
Derivative cannabis products will soon hit licensed Canadian dispensaries.
Motley Foolyesterday
Does Anheuser-Busch InBev Have Any Growth on Tap in Q2?
The brewer surprised the market last quarter, but it has a heavy debt load to carry, which weighs it down.
Market Realistyesterday
Tilray’s Stock Price Is Subdued Despite Global Opportunities
On July 19, Tilray was trading at a forward EV-to-sales multiple of 12.1x. The company was still trading at a premium to the peer median at 6.0x.
Motley Foolyesterday
Will Aurora, Canopy, Cronos, and Tilray Be Profitable by 2021?
Rapid sales growth yields no guarantee of profitability in the cannabis space.
Financial Timesyesterday
Asahi/AB InBev: amber nectar, amber warning
A big, cold beer, as the famous Australian lager ad puts it, is the answer to a hard-earned thirst. It is less enticing to those drenched in debt, even if their taste for the amber nectar has made them the world’s biggest brewer. Asahi investors have little reason to crack a tinnie.
Financial Timesyesterday
Asahi loses $2bn in market value after AB InBev deal
Japanese brewer Asahi lost more than $2bn of its market value on Monday as investors fretted about its debt load following an $11.3bn deal to buy Anheuser-Busch InBev’s Australian operations. Asahi had moved swiftly to buy Carlton & United Breweries from AB InBev after the world’s largest brewer looked to raise cash in the wake of the aborted initial public offering of its Asian business. On top of fresh debt concerns, Japan’s largest brewer has warned investors that it will issue up to $1.9bn in new equity to finance the latest acquisition, which will result in an 8.7 per cent dilution.